Swiss pharmaceutical giant Novartis (NYSE: NVS) acquired DTx Pharma for $500 million in cash, plus an additional $500 million in future payments if certain milestones are met. San Diego-based DTx Pharma is a pre-clinical biotech company that specializes in developing RNA therapies that treat disorders affecting neuromuscular and central nervous system functions.
To read the entire story, you must be logged in.
Please log in now or register with us.
